{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:40:02Z","timestamp":1758746402792,"version":"3.44.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.yapd.2008.07.015","type":"journal-article","created":{"date-parts":[[2008,9,20]],"date-time":"2008-09-20T04:30:45Z","timestamp":1221885045000},"page":"99-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cystic Fibrosis: a Review of Pulmonary and Nutritional Therapies"],"prefix":"10.1016","volume":"55","author":[{"given":"Reshma","family":"Amin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4922","key":"10.1016\/j.yapd.2008.07.015_bib1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.yapd.2008.07.015_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.yapd.2008.07.015_bib3","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Mechanisms of disease cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.yapd.2008.07.015_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970\u20131989","volume":"143","author":"Corey","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.yapd.2008.07.015_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/BF03167716","article-title":"Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis","volume":"170","author":"McCloskey","year":"2001","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3","article-title":"Current understanding of the inflammatory process in cystic fibrosis: onset and etiology","volume":"24","author":"Konstan","year":"1997","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib7","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/adc.70.2.84","article-title":"Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period","volume":"70","author":"Weaver","year":"1994","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N","article-title":"German Board of the European Registry for Cystic Fibrosis (ERCF). Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis","volume":"31","author":"Ratjen","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2008.07.015_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized control trial","volume":"140","author":"Stutman","year":"2002","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(85)92222-6","article-title":"Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis","volume":"13","author":"Littlewood","year":"1985","journal-title":"Lancet"},{"issue":"8769","key":"10.1016\/j.yapd.2008.07.015_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.yapd.2008.07.015_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2008.07.015_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatr Pulmonol"},{"issue":"44","key":"10.1016\/j.yapd.2008.07.015_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.me.44.020193.000245","article-title":"Antibiotic therapy for chronic infection of Pseudomonas in the lung","author":"Hoiby","year":"1993","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1651-2227.1983.tb09789.x","article-title":"Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection","volume":"72","author":"Szaff","year":"1983","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.yapd.2008.07.015_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"7","author":"MacLusky","year":"1989","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib21","article-title":"Nebulised anti-pseudomonal antibiotics for cystic fibrosis [review]","author":"Ryan","year":"1999","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yapd.2008.07.015_bib22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"unstructured":"Nikolaizik W, Vietzke D, Ratjen F. Comparative assessment of different inhaled tobramycin regimens to treat chronic P. aeruginosa infection in cystic fibrosis. (in press).","key":"10.1016\/j.yapd.2008.07.015_bib23"},{"key":"10.1016\/j.yapd.2008.07.015_bib24","article-title":"Evaluation of inhaled colimycin in children with cystic fibrosis","volume":"106","author":"Day","year":"1988","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.yapd.2008.07.015_bib25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.yapd.2008.07.015_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R","article-title":"Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment","volume":"21","author":"Frederiksen","year":"1996","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.yapd.2008.07.015_bib29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/37.6.1155","article-title":"Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis","volume":"37","author":"Barclay","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"9470","key":"10.1016\/j.yapd.2008.07.015_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.yapd.2008.07.015_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.03.00063402","article-title":"N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstuctive pulmonary disease","volume":"21","author":"Gerrits","year":"2003","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-4-13","article-title":"Randomised controlled trial of N-Acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease","author":"Black","year":"2004","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib34","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High dose oral N-acetylcysteine, a glutathione pro-drug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanzium","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.yapd.2008.07.015_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ppul.20134","article-title":"DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha","volume":"39","author":"Ratjen","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib38","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1378\/chest.128.4.2327","article-title":"Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis","volume":"128","author":"Robinson","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/thx.51.2.119","article-title":"In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis","volume":"51","author":"Shah","year":"1996","journal-title":"Thorax"},{"issue":"6 Pt 1","key":"10.1016\/j.yapd.2008.07.015_bib40","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1164\/ajrccm.153.6.8665055","article-title":"Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations","volume":"153","author":"Wilmott","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib41","first-page":"919","article-title":"Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease","volume":"148","author":"Sheils","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.yapd.2008.07.015_bib42","series-title":"Cilia mucus and mucociliary interactions","first-page":"333","article-title":"DNA and actin filaments ultrastructure in cystic fibrosis sputum","author":"Tomkiewicz","year":"1998"},{"issue":"5149","key":"10.1016\/j.yapd.2008.07.015_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1126\/science.8310295","article-title":"Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin","volume":"263","author":"Vasconcellos","year":"1994","journal-title":"Science"},{"year":"1996","author":"Dasgupta","series-title":"Rheological properties in cystic fibrosis and airway secretions with combined rhDNase and gelsolin treatment, in Advances in physiological fluid dynamics","key":"10.1016\/j.yapd.2008.07.015_bib44"},{"key":"10.1016\/j.yapd.2008.07.015_bib45","article-title":"Oral steroids for cystic fibrosis","volume":"2","author":"Cheng","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","article-title":"A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group","volume":"126","author":"Eigen","year":"1995","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.yapd.2008.07.015_bib47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCP.0b013e3282ef9806","article-title":"Anti-inflammatory approaches to cystic fibrosis airways disease","volume":"13","author":"Balfour-Lynn","year":"2007","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jcf.2006.12.009","article-title":"Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey","volume":"6","author":"Hester","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib49","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1378\/chest.07-0843","article-title":"Oral corticosteroid therapy in cystic fibrosis patients hospitalized with for pulmonary exacerbation: a pilot study","volume":"132","author":"Dovey","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/(SICI)1099-0496(199707)24:1<48::AID-PPUL8>3.0.CO;2-F","article-title":"Lower respiratory illness in infants and young children with cystic fibrosis: evaluation of treatment with intravenous hydrocortisone","volume":"24","author":"Tepper","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2008.07.015_bib51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-6-17","article-title":"A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients","volume":"6","author":"Lucidi","year":"2006","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001915","article-title":"Inhaled corticosteroids for cystic fibrosis","volume":"2","author":"Balfour-Lynn","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yapd.2008.07.015_bib53","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1164\/rccm.200511-1808OC","article-title":"CF WISE(Withdrawal of Inhaled Steroids Evaluation) investigators. Multicenter randomized controlled trial of withdrawal of inhaled corticostreoids in cystic fibrosis","volume":"173","author":"Balfour-Lynn","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00431-006-0198-9","article-title":"Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?","volume":"166","author":"De Boeck","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/ard.36.3.239","article-title":"Action of nonsteroidal, anti-inflammatory drugs on human and rat peripheral leucocyte migration in vitro","volume":"36","author":"Brown","year":"1977","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.yapd.2008.07.015_bib56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/BF01968260","article-title":"Inhibition of human leucocytes locomotion by anti-inflammatory drugs","volume":"35","author":"Spisani","year":"1979","journal-title":"Experientia"},{"key":"10.1016\/j.yapd.2008.07.015_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0014-2999(80)90297-6","article-title":"The effects of non-steroid anti-inflammatory drugs on\u00a0leukocyte migration in carrageenin-induced inflammation","volume":"66","author":"Higgs","year":"1980","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yapd.2008.07.015_bib58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00916277","article-title":"Modulation of leukotaxis by ibuprofen: a quantitative determination in vivo","volume":"9","author":"Shimanuki","year":"1985","journal-title":"Inflammation"},{"key":"10.1016\/j.yapd.2008.07.015_bib59","first-page":"118","article-title":"Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa","volume":"67","author":"Sordelli","year":"1985","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.yapd.2008.07.015_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000441-198601000-00007","article-title":"Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia","volume":"291","author":"Rinaldo","year":"1986","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.yapd.2008.07.015_bib61","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/infdis\/152.4.690","article-title":"Effects of the newer nonsteroidal anti-inflammatory agents ibuprofen, fenoprofen, and sulindac on neutrophil adherence","volume":"152","author":"Venezio","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.yapd.2008.07.015_bib62","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/jps.2600731020","article-title":"Inhibition of human polymorphonuclear leukocyte cell responses by ibuprofen","volume":"73","author":"Maderazo","year":"1984","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.yapd.2008.07.015_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0006-2952(84)90228-4","article-title":"Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo","volume":"33","author":"Kaplan","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.yapd.2008.07.015_bib64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00918351","article-title":"Ibuprofen inhibits granulocyte responses to inflammatory mediators: a proposed mechanism for reduction of experimental myocardial infarct size","volume":"8","author":"Flynn","year":"1984","journal-title":"Inflammation"},{"key":"10.1016\/j.yapd.2008.07.015_bib65","first-page":"152","article-title":"Effect of ibuprofen on neutrophil (PMN) delivery to mucosal surfaces","volume":"4","author":"Konstan","year":"1989","journal-title":"Pediatr Pulmonol Suppl"},{"issue":"13","key":"10.1016\/j.yapd.2008.07.015_bib66","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00151829-200504040-00004","article-title":"Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent","volume":"4","author":"Chmiel","year":"2005","journal-title":"Treat Respir Med"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2006.06.003","article-title":"Use of high-dose ibuprofen in a pediatric cystic fibrosis center","volume":"6","author":"Fennell","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial","volume":"151","author":"Lands","year":"2007","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001505.pub2","article-title":"Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis","volume":"17","author":"Lands","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.yapd.2008.07.015_bib71","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/ajrccm\/148.4_Pt_1.896","article-title":"Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis","volume":"148","author":"Konstan","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm\/141.1.186","article-title":"Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis","volume":"141","author":"Konstan","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.yapd.2008.07.015_bib74","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1081-1206(10)62108-4","article-title":"Anti-inflammatory effects of montelukast in mild cystic fibrosis","volume":"89","author":"Schmitt-Grohe","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3\u20134","key":"10.1016\/j.yapd.2008.07.015_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000195915","article-title":"Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis","volume":"58","author":"Nagai","year":"1991","journal-title":"Respiration"},{"issue":"9338","key":"10.1016\/j.yapd.2008.07.015_bib76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"issue":"13","key":"10.1016\/j.yapd.2008.07.015_bib78","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.yapd.2008.07.015_bib79","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.200502-218OC","article-title":"Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis","volume":"172","author":"Saiman","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.rmed.2005.07.016","article-title":"Exploring the mechanisms of macrolides in cystic fibrosis","volume":"100","author":"Equi","year":"2006","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.yapd.2008.07.015_bib81","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.yapd.2008.07.015_bib82","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/adc.2004.069419","article-title":"New insights into pulmonary inflammation in cystic fibrosis","volume":"91","author":"Rao","year":"2006","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib84","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkl014","article-title":"Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis","volume":"57","author":"Phaff","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.inf.0000247109.44249.ac","article-title":"Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function","volume":"26","author":"Tramper-Stranders","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.yapd.2008.07.015_bib86","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0140-6736(91)91167-S","article-title":"Aerosol alpha1-antitrypsin treatment for cystic fibrosis","volume":"337","author":"McElvaney","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.yapd.2008.07.015_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ppul.20345","article-title":"Recombinant AAT CF study team: safety and efficacy of\u00a0recombinant alpha1 antitrypsin therapy in cystic fibrosis","volume":"41","author":"Martin","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2008.07.015_bib88","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00047306","article-title":"\u03b11-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients","volume":"29","author":"Griese","year":"2007","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.yapd.2008.07.015_bib89","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200308-1104OC","article-title":"Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis","volume":"169","author":"Griese","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"2 Pt 1","key":"10.1016\/j.yapd.2008.07.015_bib91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1152\/ajpcell.1989.256.2.C226","article-title":"Activation of an apical Cl- conductance by Ca2+ ionophores in cystic fibrosis airway epithelia","volume":"256","author":"Willumsen","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.yapd.2008.07.015_bib92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCP.0b013e3282efbc56","article-title":"New pulmonary therapies for cystic fibrosis","volume":"13","author":"Ratjen","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1097-2765(01)00286-6","article-title":"The CF salt controversy: in vivo observations and therapeutic approaches","volume":"8","author":"Tarran","year":"2001","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.yapd.2008.07.015_bib94","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199108223250802","article-title":"Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis","volume":"325","author":"Knowles","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.yapd.2008.07.015_bib95","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1165\/ajrcmb.23.6.4207","article-title":"Inhibition of amiloride-sensitive epithelial Na(+) absorption by extracellular nucleotides in human normal and cystic fibrosis airways","volume":"23","author":"Mall","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4 Pt 1","key":"10.1016\/j.yapd.2008.07.015_bib96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1152\/ajpcell.1999.276.4.C827","article-title":"UTP inhibits Na+ absorption in wild-type and DeltaF508 CFTR-expressing human bronchial epithelia","volume":"276","author":"Devor","year":"1999","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.yapd.2008.07.015_bib97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ppul.20192","article-title":"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","volume":"39","author":"Deterding","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.yapd.2008.07.015_bib98","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/thx.40.11.832","article-title":"Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction","volume":"40","author":"British Thoracic Society Research Committee","year":"1985","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib99","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/030006058401200206","article-title":"Irish general practice study of acetylcysteine (Fabrol) in chronic bronchitis","volume":"12","author":"Tattersall","year":"1984","journal-title":"J Int Med Res"},{"issue":"5","key":"10.1016\/j.yapd.2008.07.015_bib100","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1378\/chest.06-2085","article-title":"Inhalation of Moli1901 in patients with cystic fibrosis","volume":"131","author":"Grasemann","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib101","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1085\/jgp.118.2.223","article-title":"The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition","volume":"118","author":"Tarran","year":"2001","journal-title":"J Gen Physiol"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.prrv.2007.02.008","article-title":"Other mucoactive agents for cystic fibrosis","volume":"8","author":"Bye","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"3 Pt 1","key":"10.1016\/j.yapd.2008.07.015_bib104","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/ajrccm.156.3.9701113","article-title":"A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol","volume":"156","author":"Anderson","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"10.1016\/j.yapd.2008.07.015_bib105","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(06)80042-1","article-title":"Inhaled dry powder mannitol (Bronchitol) improves FEV1 in cystic fibrosis","volume":"5","author":"Charlton","year":"2006","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib106","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1034\/j.1399-3003.1999.14c30.x","article-title":"The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study","volume":"14","author":"Robinson","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.yapd.2008.07.015_bib107","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0003-9861(70)90371-1","article-title":"Transport and phosphorylation of glucose, fructose, and mannitol by Pseudomonas aeruginosa","volume":"138","author":"Phibbs","year":"1970","journal-title":"Arch Biochem Biophys"},{"issue":"9","key":"10.1016\/j.yapd.2008.07.015_bib108","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1139\/o71-151","article-title":"Kinetics of transport of glucose, fructose, and mannitol by Pseudomonas aeruginosa","volume":"49","author":"Eagon","year":"1971","journal-title":"Can J Biochem"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib109","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I","volume":"156","author":"King","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.yapd.2008.07.015_bib110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1172\/JCI119138","article-title":"Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea","volume":"99","author":"Wills","year":"1997","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.yapd.2008.07.015_bib111","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/ajrccm.153.5.8630593","article-title":"Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis","volume":"153","author":"Robinson","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.yapd.2008.07.015_bib112","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/thx.52.10.900","article-title":"Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis","volume":"52","author":"Robinson","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.yapd.2008.07.015_bib113","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.yapd.2008.07.015_bib114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ppul.20603","article-title":"Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis","volume":"42","author":"Subbarao","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"S29","key":"10.1016\/j.yapd.2008.07.015_bib115","first-page":"292","article-title":"Tolerability of hypertonic saline when delivered rapidly via the eFlow rapid nebulizer in subjects with cystic fibrosis","volume":"41","author":"Elkins","year":"2006","journal-title":"Pediatr Pulmonol"},{"issue":"14","key":"10.1016\/j.yapd.2008.07.015_bib116","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.gt.3302809","article-title":"Gene therapy progress and prospects: cystic fibrosis","volume":"13","author":"Griesenbach","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.yapd.2008.07.015_bib117","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/sj.gt.3302290","article-title":"Effect of Pseudomonas-induced chronic lung inflammation on specific cytotoxic T-cell responses to adenoviral vectors in mice","volume":"11","author":"Tosi","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.yapd.2008.07.015_bib118","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.yapd.2008.07.015_bib119","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2007.022","article-title":"Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial","volume":"18","author":"Moss","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.yapd.2008.07.015_bib121","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.prrv.2006.04.213","article-title":"Mutation specific therapy in CF","volume":"7","author":"Kerem","year":"2006","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.yapd.2008.07.015_bib122","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamycin suppresses preamture stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"3pt1","key":"10.1016\/j.yapd.2008.07.015_bib123","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamycin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J\u00a0Respir Crit Care Med"},{"key":"10.1016\/j.yapd.2008.07.015_bib124","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamycin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"unstructured":"ClinicalTrials.gov reference number NCT00016744.","key":"10.1016\/j.yapd.2008.07.015_bib125"},{"year":"2006","author":"Chernick","series-title":"Nonpulmonary manifestations of cystic fibrosis, in Kendig's respiratory diseases in children (7th edition)","key":"10.1016\/j.yapd.2008.07.015_bib126"},{"key":"10.1016\/j.yapd.2008.07.015_bib127","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1067\/mpd.2003.152","article-title":"Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis","volume":"142","author":"Konstan","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib128","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-8223(01)00113-4","article-title":"Stature as a prognostic factor in cystic fibrosis survival","volume":"101","author":"Beker","year":"2001","journal-title":"J\u00a0Am Diet Assoc"},{"key":"10.1016\/j.yapd.2008.07.015_bib129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/03014469400003242","article-title":"The adolescent growth spurt in chidlren with cystic fibrosis","volume":"21","author":"Byard","year":"1994","journal-title":"Ann Hum Biol"},{"issue":"Suppl 1","key":"10.1016\/j.yapd.2008.07.015_bib130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/eje.0.151s081","article-title":"GH improves growth and clinical status in children with cystic fibrosis: a review of published studies","volume":"151","author":"Hardin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.yapd.2008.07.015_bib131","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI119207","article-title":"Interleukin 6 causes growth impairment in transgenic mice through a decrease ininsulin-like growth factor-I. A model for stunted growth in children with chronic inflammation","volume":"99","author":"De Benedetti","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.yapd.2008.07.015_bib132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-277X.1995.tb00311.x","article-title":"Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study","volume":"8","author":"Sackey","year":"1995","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.yapd.2008.07.015_bib133","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N","article-title":"Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients","volume":"22","author":"Huseman","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.yapd.2008.07.015_bib134","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0022-3476(97)70015-5","article-title":"Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience","volume":"131","author":"Hardin","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib135","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1055\/s-2007-978949","article-title":"Growth hormone improves weight velocity and height velocity in children with cystic fibrosis","volume":"30","author":"Hardin","year":"1998","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.yapd.2008.07.015_bib136","first-page":"209","article-title":"Effects of growth hormone therapy on bone metabolism in patients with cystic fibrosis","author":"Schnabel","year":"1998","journal-title":"Pediatric Osteology"},{"key":"10.1016\/j.yapd.2008.07.015_bib137","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1067\/mpd.2001.117578","article-title":"Growth hormone improves clinical status in children with cystic fibrosis\u2014results of a randomized controlled trial","volume":"139","author":"Hardin","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib138","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/07315724.1998.10718788","article-title":"Anabolic effects of growth hormone treatment in young children with cystic fibrosis","volume":"17","author":"Alemazadeh","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.yapd.2008.07.015_bib139","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2006-1101","article-title":"Growth hormone treatment improves growth and clinical status in prepubertal chidlren with cystic fibrosis: results of a multicenter randomized controlled trial","volume":"91","author":"Hardin","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.yapd.2008.07.015_bib140","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1542\/peds.2006-2783","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis","volume":"119","author":"Schnabel","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib141","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpeds.2005.03.043","article-title":"Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis","volume":"147","author":"Schneiderman-Walker","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib142","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3476(88)80315-9","article-title":"Diabetes mellitus associated with cystic fibrosis","volume":"112","author":"Finkelstein","year":"1988","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.yapd.2008.07.015_bib143","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/adc.66.5.612","article-title":"Glucose tolerance in cystic fibrosis","volume":"66","author":"Lanng","year":"1991","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.yapd.2008.07.015_bib144","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J pediatr"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib145","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.yapd.2008.07.015_bib146","first-page":"222","article-title":"Paediatric cystic fibrosis related diabetes","volume":"8","author":"Campbell","year":"2004","journal-title":"Journal of Diabetes Nursing"},{"issue":"3","key":"10.1016\/j.yapd.2008.07.015_bib148","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMe058293","article-title":"Restoring airway surface liquid in cystic fibrosis","volume":"354","author":"Ratjen","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310108000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310108000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:10:43Z","timestamp":1758744643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310108000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0065310108000169"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2008.07.015","relation":{},"ISSN":["0065-3101"],"issn-type":[{"type":"print","value":"0065-3101"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic Fibrosis: a Review of Pulmonary and Nutritional Therapies","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2008.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}